Next Investors logo grey

Hemp demand sees Elixinol fly high with outstanding revenue growth


Published 19-FEB-2019 10:55 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Shares in Elixinol Global Ltd (ASX:EXL; OTCQX:ELLXF) have surged in February after the company announced outstanding year-on-year revenue growth for both the December quarter and calendar year 2018.

Elixinol is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado, US.

Elixinol Global has an international presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products.

December quarter revenue of $11.9 million was up 116% on the same quarter a year ago, while its full-year revenue of $37.2 million was more than double 2017 revenues of $16.8 million.

Next Investors Image

While many stocks in the cannabis sector have run hard in the last 12 months, the recent performance of Elixinol comes on the back of the strong financial performance we just referred to as well as some important operational developments within the group.

From a financial perspective, is also worth noting that the company had $42.9 million in cash and only $250,000 in debt, as at December 31, 2018, providing the company with a strong platform for its expansionary plans.

International footprint

Such is the growing interest in the stock that the company’s shares increased 15% on Thursday and Friday of last week, with Friday’s surge supported by all-time record trading volumes.

Analysts note changing landscape in the US

Elixinol is also being assisted by industry changing reforms in the US.

While much has been documented about the increasing global acceptance of medicinal cannabis use, analysts at Bell Potter recently highlighted the structural changes occurring in the US saying, “The category has continued to experience explosive revenue growth which we now believe will further accelerate with the passing of the 2018 Farm Bill in the US.

“The Bill reclassifies industrial hemp off the controlled substances act and the growing of hemp will now be regulated by the US Department of Agriculture.

“In our view this is another important step toward industrial hemp products becoming mainstream in the US.

“Recently, the FDA approved the first medicinal cannabis product in the US for the treatment of epilepsy in children.

“In our view this event is likely to have a flow on effect for other market participants including for the over the counter hemp CBD products marketed by Elixinol US.”

Next Investors Image

Australian manufacturing site in NSW

The Australian operations of the group include Hemp Foods Australia, a company focused on the development of the market for Hemp Foods.

Founded in 1999, Hemp Foods Australia, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products.

Elixinol’s recently acquired a property in the Northern Rivers district of NSW to establish its Australian medical cannabis cultivation and manufacturing facility appeared to be a key driver behind the surge in its share price.

Management’s large stake provides confidence

Elixinol is led by Chief Executive Paul Benhaim who is the co-founder of both Elixinol US and Health Foods Australia.

Following the most recent capital raising he retains a 62% shareholding, aligning his interests strongly with his fellow shareholders.

Benhaim is an expert in the field of industrial hemp and medicinal cannabis following more than two decades of experience in the sector in Australia, the US and Europe.

Consequently, with highly experienced and committed management, establish revenues, a strong growth profile and broadening industry opportunities emerging as regulatory changes are executed, Elixinol is poised to benefit from its position as a vertically integrated business.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.